E.U. Recommends Novartis' CV Combo Rasilamlo
This article was originally published in The Pink Sheet Daily
Executive Summary
European regulators recommend approval of yet another combination antihypertensive from Novartis as the Swiss company attempts to soften the loss of patent protection on its blockbuster Diovan.